Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for ...

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 18 August 2026 · Fusion42 review

858 Therapeutics received FDA Fast Track designation for ETX-19477, a PARG inhibitor targeting BRCA-mutated HR+/HER2- unresectable or metastatic breast cancer, allowing expedited regulatory review and potential accelerated approval.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You gain a faster regulatory path for advanced breast cancer treatment with BRCA mutations, opening quicker access to US markets and patients. This sets a new benchmark for developers in oncology targeting similar genetic profiles.

◆ Coverage

1 source · 18 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-fast-trackbreast-cancerparg-inhibitoroncologyclinical-trials